PECAM-1 mediates temsirolimus-induced increase in neutrophil transendothelial migration that leads to lung injury

X Chen, J Chen, S Liu, X Li - Biochemical and Biophysical Research …, 2023 - Elsevier
Temsirolimus is a first-generation mTOR inhibitor commonly used in the clinical treatment of
cancers that is associated with lung injury. However, the mechanism underlying this adverse …
被引用次数：1 相关文章

PECAM-1 mediates temsirolimus-induced increase in neutrophil transendothelial migration that leads to lung injury.

X Chen, J Chen, S Liu, X Li - Biochemical and Biophysical …, 2023 - europepmc.org
Temsirolimus is a first-generation mTOR inhibitor commonly used in the clinical treatment of
cancers that is associated with lung injury. However, the mechanism underlying this adverse …

PECAM-1 mediates temsirolimus-induced increase in neutrophil transendothelial migration that leads to lung injury

X Chen, J Chen, S Liu, X Li - Biochemical and biophysical … - pubmed.ncbi.nlm.nih.gov
Temsirolimus is a first-generation mTOR inhibitor commonly used in the clinical treatment of
cancers that is associated with lung injury. However, the mechanism underlying this adverse …